קפיטליזציית שוק: YmAbs (YMAB)

Y-mAbs Therapeutics (YMAB) focuses on developing targeted therapies for children by leveraging strategic alliances and the acquisition of antibody patents. This price chart on GURU.Markets, where the market capitalization stands at 0.39, complements data regarding the collaboration with the Memorial Sloan Kettering center to develop new drugs. Stable sales of approved treatments provide the cash flow necessary to fund ongoing scientific research.

Market capitalization is calculated as the product of the current share price and the total number of outstanding shares. This aggregate metric reflects the market's collective valuation of all the issuer's assets and future cash flows. For Y-mAbs Therapeutics (YMAB), the volatility of this metric is driven by geopolitical barriers that hinder the export of oncology drugs and the conduct of international trials. The company's market capitalization trend on the exchange reflects investor reaction to these logistical risks. A stable trend in this curve confirms the viability of the business model.